loading
Precedente Chiudi:
$568.20
Aprire:
$567.34
Volume 24 ore:
80,595
Relative Volume:
0.08
Capitalizzazione di mercato:
$59.22B
Reddito:
$14.21B
Utile/perdita netta:
$4.46B
Rapporto P/E:
14.33
EPS:
39.68
Flusso di cassa netto:
$3.56B
1 W Prestazione:
-0.82%
1M Prestazione:
+2.18%
6M Prestazione:
-17.52%
1 anno Prestazione:
-51.16%
Intervallo 1D:
Value
$562.83
$570.00
Intervallo di 1 settimana:
Value
$552.81
$571.20
Portata 52W:
Value
$476.49
$1,170.58

Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile

Name
Nome
Regeneron Pharmaceuticals Inc
Name
Telefono
(914) 847-7000
Name
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Name
Dipendente
15,207
Name
Cinguettio
@regeneron
Name
Prossima data di guadagno
2025-08-01
Name
Ultimi documenti SEC
Name
REGN's Discussions on Twitter

Confronta REGN con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
568.52 58.91B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
396.03 99.62B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
474.31 61.52B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
767.47 46.69B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
330.47 34.54B 3.81B -644.79M -669.77M -6.24

Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-08-14 Iniziato Rothschild & Co Redburn Buy
2025-06-30 Downgrade Argus Buy → Hold
2025-05-30 Downgrade RBC Capital Mkts Outperform → Sector Perform
2025-05-30 Downgrade Wells Fargo Overweight → Equal Weight
2025-05-14 Aggiornamento Citigroup Neutral → Buy
2025-04-22 Ripresa Cantor Fitzgerald Overweight
2025-02-05 Aggiornamento Leerink Partners Market Perform → Outperform
2025-01-16 Downgrade UBS Buy → Neutral
2024-12-10 Ripresa BofA Securities Underperform
2024-11-15 Iniziato Wolfe Research Outperform
2024-11-14 Iniziato Citigroup Neutral
2024-09-24 Downgrade Leerink Partners Outperform → Market Perform
2024-03-12 Iniziato Bernstein Outperform
2024-01-12 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2023-11-09 Iniziato Deutsche Bank Hold
2023-11-03 Aggiornamento Raymond James Mkt Perform → Outperform
2023-08-21 Aggiornamento Canaccord Genuity Hold → Buy
2023-08-21 Reiterato Oppenheimer Perform
2023-06-28 Downgrade Canaccord Genuity Buy → Hold
2023-03-27 Aggiornamento SVB Securities Market Perform → Outperform
2023-03-24 Aggiornamento Jefferies Hold → Buy
2023-03-23 Aggiornamento Raymond James Underperform → Mkt Perform
2023-01-30 Aggiornamento Cowen Market Perform → Outperform
2023-01-20 Aggiornamento JP Morgan Neutral → Overweight
2022-10-26 Downgrade Raymond James Mkt Perform → Underperform
2022-10-17 Downgrade Evercore ISI Outperform → In-line
2022-09-09 Aggiornamento Jefferies Underperform → Hold
2022-09-09 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2022-07-25 Downgrade SVB Leerink Outperform → Mkt Perform
2022-07-13 Iniziato Cantor Fitzgerald Neutral
2022-06-06 Iniziato Jefferies Underperform
2022-05-23 Iniziato SVB Leerink Outperform
2022-01-05 Downgrade BofA Securities Neutral → Underperform
2022-01-03 Aggiornamento Bernstein Mkt Perform → Outperform
2021-12-15 Downgrade Bernstein Outperform → Mkt Perform
2021-12-09 Ripresa Wells Fargo Overweight
2021-12-07 Ripresa Cowen Market Perform
2021-12-06 Iniziato Goldman Buy
2021-11-19 Ripresa BMO Capital Markets Outperform
2021-11-05 Downgrade The Benchmark Company Buy → Hold
2021-06-29 Iniziato H.C. Wainwright Buy
2021-01-25 Aggiornamento BMO Capital Markets Market Perform → Outperform
2021-01-13 Aggiornamento The Benchmark Company Hold → Buy
2021-01-08 Aggiornamento Citigroup Neutral → Buy
2020-10-05 Aggiornamento Cantor Fitzgerald Neutral → Overweight
2020-08-20 Downgrade The Benchmark Company Buy → Hold
2020-07-09 Aggiornamento SunTrust Hold → Buy
2020-05-26 Aggiornamento Wells Fargo Equal Weight → Overweight
2020-04-28 Downgrade Citigroup Buy → Neutral
2020-04-17 Aggiornamento The Benchmark Company Hold → Buy
2020-04-08 Iniziato The Benchmark Company Hold
2020-03-31 Iniziato Wolfe Research Peer Perform
2020-02-27 Iniziato Barclays Overweight
2020-02-26 Aggiornamento Canaccord Genuity Hold → Buy
2020-02-26 Downgrade Robert W. Baird Outperform → Neutral
2020-02-25 Aggiornamento Jefferies Hold → Buy
2020-02-11 Aggiornamento Argus Hold → Buy
2019-12-24 Iniziato Raymond James Mkt Perform
2019-12-16 Downgrade Evercore ISI Outperform → In-line
2019-12-13 Aggiornamento Credit Suisse Neutral → Outperform
2019-11-12 Iniziato SunTrust Hold
2019-11-07 Aggiornamento Citigroup Neutral → Buy
2019-10-17 Ripresa BofA/Merrill Neutral
2019-09-23 Aggiornamento Guggenheim Neutral → Buy
Mostra tutto

Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie

pulisher
07:42 AM

Ilmarinen Mutual Pension Insurance Co Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

07:42 AM
pulisher
07:28 AM

Ascent Group LLC Purchases 937 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

07:28 AM
pulisher
07:04 AM

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Cuts Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

07:04 AM
pulisher
03:11 AM

Sepio Capital LP Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

03:11 AM
pulisher
12:17 PM

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

12:17 PM
pulisher
Sep 11, 2025

Scientech Research LLC Has $1.21 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Sep 11, 2025
pulisher
Sep 11, 2025

Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Tamar Securities LLC - MarketBeat

Sep 11, 2025
pulisher
Sep 11, 2025

Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Woodline Partners LP - MarketBeat

Sep 11, 2025
pulisher
Sep 11, 2025

Banque Transatlantique SA Reduces Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Sep 11, 2025
pulisher
Sep 11, 2025

Teza Capital Management LLC Has $251,000 Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Sep 11, 2025
pulisher
Sep 11, 2025

Regeneron Pharmaceuticals, Inc. $REGN Holdings Increased by UniSuper Management Pty Ltd - MarketBeat

Sep 11, 2025
pulisher
Sep 11, 2025

Focus Partners Advisor Solutions LLC Invests $538,000 in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Sep 11, 2025
pulisher
Sep 10, 2025

DnB Asset Management AS Purchases 14,323 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Sep 10, 2025
pulisher
Sep 10, 2025

Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Nissay Asset Management Corp Japan ADV - MarketBeat

Sep 10, 2025
pulisher
Sep 10, 2025

MAI Capital Management Has $566,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Sep 10, 2025
pulisher
Sep 10, 2025

United Services Automobile Association Buys Shares of 2,477 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Sep 10, 2025
pulisher
Sep 09, 2025

Sandoz, Regeneron Settle Eye Drug Patent Claims - Law360

Sep 09, 2025
pulisher
Sep 09, 2025

Regeneron’s fast-acting IgG promises alternative to frequent allergy shots - biocentury.com

Sep 09, 2025
pulisher
Sep 09, 2025

Gotham Asset Management LLC Purchases 20,624 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Sep 09, 2025
pulisher
Sep 09, 2025

REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire

Sep 09, 2025
pulisher
Sep 09, 2025

REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire Inc.

Sep 09, 2025
pulisher
Sep 09, 2025

Regeneron's Libtayo Combo Achieves Nearly Double Survival Rate In Advanced Lung Cancer Compared To Chemotherapy - AOL.com

Sep 09, 2025
pulisher
Sep 09, 2025

Alliancebernstein L.P. Decreases Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Sep 09, 2025
pulisher
Sep 09, 2025

AQR Capital Management LLC Purchases 28,865 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Sep 09, 2025
pulisher
Sep 09, 2025

Can You Keep The Cat and The Relationship? Regeneron Thinks So - insights.citeline.com

Sep 09, 2025
pulisher
Sep 09, 2025

A Look at Regeneron (REGN) Valuation After Positive Phase 3 Results in Myasthenia Gravis Trial - simplywall.st

Sep 09, 2025
pulisher
Sep 09, 2025

Regeneron Deal Lets Sandoz Launch Eylea Biosimilar in Late 2026 - Bloomberg Law News

Sep 09, 2025
pulisher
Sep 09, 2025

Regeneron’s cat and birch allergy mAbs score in Phase III trials - Yahoo Finance

Sep 09, 2025
pulisher
Sep 09, 2025

Sandoz and Regeneron reach agreement over biosimilar dispute - Ophthalmology Times

Sep 09, 2025
pulisher
Sep 09, 2025

Regeneron settles patent dispute with Sandoz over Eylea biosimilar - Seeking Alpha

Sep 09, 2025
pulisher
Sep 09, 2025

Regeneron’s Antibodies Block Cat and Birch Allergies With ‘Robust Activity’ - BioSpace

Sep 09, 2025
pulisher
Sep 09, 2025

Libtayo plus chemotherapy results at five years reinforce significant and durable improvements in survival - MarketScreener

Sep 09, 2025
pulisher
Sep 09, 2025

Sandoz Eyes 2026 Aflibercept Launch With Regeneron Eylea Settlement - insights.citeline.com

Sep 09, 2025
pulisher
Sep 09, 2025

Sandoz and Regeneron settle aflibercept dispute, paving way for US debut - The Pharma Letter

Sep 09, 2025
pulisher
Sep 09, 2025

Five-Year Data from Regeneron's EMPOWER-Lung 3 Trial Shows Libtayo Plus Chemotherapy Significantly Improves Overall Survival in Advanced NSCLC Patients - Quiver Quantitative

Sep 09, 2025
pulisher
Sep 09, 2025

19.4% vs 8.8%: Regeneron's Libtayo Doubles Long-term Survival in Advanced Lung Cancer Trial at 5 Years - Stock Titan

Sep 09, 2025
pulisher
Sep 09, 2025

Sandoz reaches agreement with Regeneron, resolving all patent litigation related to its US aflibercept biosimilar - Sandoz

Sep 09, 2025
pulisher
Sep 08, 2025

Regeneron Says Experimental Therapy Reduced Symptoms Of Cat, Birch Allergies In Late-Stage Trials - Stocktwits

Sep 08, 2025
pulisher
Sep 08, 2025

Flputnam Investment Management Co. Sells 5,992 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Sep 08, 2025
pulisher
Sep 08, 2025

Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Raymond James Financial - MarketBeat

Sep 08, 2025
pulisher
Sep 08, 2025

Royal Bank of Canada Trims Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Sep 08, 2025
pulisher
Sep 08, 2025

What's Happening With Regeneron Pharmaceuticals Stock On Monday? - Benzinga

Sep 08, 2025
pulisher
Sep 08, 2025

Regeneron's allergen-blocking antibodies score phase 3 wins against cat, pollen allergies - Fierce Biotech

Sep 08, 2025
pulisher
Sep 08, 2025

Samlyn Capital LLC Makes New $29.12 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Sep 08, 2025
pulisher
Sep 08, 2025

Transcript : Regeneron Pharmaceuticals, Inc. Presents at Morgan Stanley 23rd Annual Global Healthcare Conference, Sep-08-2025 07 - MarketScreener

Sep 08, 2025
pulisher
Sep 08, 2025

Regeneron Pharmaceuticals Said Phase 3 Trials of Invetigational Allergy Drug Meets Primary, Secondary Endpoints - MarketScreener

Sep 08, 2025
pulisher
Sep 08, 2025

Regeneron advances allergy pipeline with positive Phase 3 trial results By Investing.com - Investing.com Canada

Sep 08, 2025
pulisher
Sep 08, 2025

Regeneron advances allergy pipeline with positive Phase 3 trial results - Investing.com

Sep 08, 2025
pulisher
Sep 08, 2025

Regeneron Pharmaceuticals, Inc. Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-In-Class Antibody-Blockers of Cat and Birch Allergies - MarketScreener

Sep 08, 2025
pulisher
Sep 08, 2025

Regeneron advances allergy pipeline with two positive Phase 3 trials evaluating antibody-blockers - MarketScreener

Sep 08, 2025
pulisher
Sep 08, 2025

Regeneron antibody treatments show promise against cat and birch allergies - Investing.com

Sep 08, 2025

Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$469.61
price up icon 0.13%
$762.81
price up icon 0.10%
biotechnology ONC
$332.38
price down icon 0.98%
$146.21
price up icon 0.27%
$101.36
price down icon 3.49%
Capitalizzazione:     |  Volume (24 ore):